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Abstract 
 
Purpose of review 
The World Health Organization recommends Pre-Exposure Prophylaxis (PrEP) in populations at 
substantial risk of HIV. Despite a number of randomized controlled trials demonstrating its efficacy, 
and several ongoing implementation projects, PrEP is currently only available in a few countries. 
Modelling studies can provide useful insights into the long term impact of introducing PrEP in 
different subgroups of the population. This review summarizes studies that either evaluated the 
cost–effectiveness or the cost of introducing PrEP, focusing on seven published in the last year. 
Recent findings 
These studies used a number of different types of models and investigated the introduction of PrEP 
in different settings. Among men having sex with men in North America, PrEP ranged from being 
cost-saving (while benefiting population health) to costing $160,000/quality-adjusted life-year 
gained. Among heterosexual sero-different couples it varied from around $5,000 to 
$10,000/disability-adjusted life-year averted, when PrEP was used until six or twelve months after 
the HIV positive partner had initiated ART in, respectively, Uganda and South Africa.  
Summary 
Future cost-effectiveness studies of PrEP should consider the HIV incidence, the level of uptake, the 
effect of its introduction on  alternative  prevention approaches and the budget impact of rolling it 
out. 
 
Keywords:  cost–effectiveness, affordability, HIV prevention, modelling, pre-exposure prophylaxis  
Introduction 
Several guidelines and position statements have been issued recommending PrEP in people at high 
risk of contracting HIV to prevent HIV acquisition (See Table 1). The use of daily oral Truvada in HIV 
negative people has been approved in the US in 2012(10), while, in most countries, including Europe 
and Australia, PrEP is not available so far.  Importantly, the World Health Organization (WHO) and 
the position released by the relevant medical associations in the UK highlighted the importance of 
estimating the cost-effectiveness of PrEP. WHO, in particular, reviewed the published literature on 
the cost-effectiveness of PrEP and took this into account when determining the strength of the 
evidence in the guidelines for key populations. WHO announced in July 2015 that updated guidance 
on PrEP will be released soon(11).    
 
The strong evidence for the effectiveness of PrEP leaves countries and health providers facing  the 
decision of whether to fund PrEP on top of the other HIV prevention programmes already in place 
and, if so, to decide which subgroups should receive it. Mathematical models provide a framework 
to combine all the information available on PrEP (uptake, efficacy, effectiveness, adherence, sexual 
behaviour while on PrEP, monitoring on PrEP and cost) to provide insights into the potential 
epidemiological impact, budget impact and cost-effectiveness of PrEP at a population level. A cost-
effectiveness analysis compares the cost and outcomes of two or more different options and  usually 
involves calculation of the cost of obtaining a gain in health (years of life, quality-adjusted life-years 
(QALY), deaths averted, infections averted, or disability-adjusted life-years (DALYs) averted).  The 
advantage of calculating the cost per QALY gained (or, similarly, per DALY averted) is that this 
“incremental cost-effectiveness ratio” (ICER) can be compared across other interventions in any 
disease area.  Budget impact analysis, on the other hand, consists of  “assessing the financial 
consequences of the introduction of a new technology in a specific setting in the short-to-medium 
term” (21). These methods have only been relatively recently developed, but they are becoming 
more and more popular, as countries need to understand, not only whether new interventions 
would be cost-effective, but as well whether they can afford the introduction of these new 
technologies.   
In this paper, we review studies which evaluated the  cost-effectiveness and/or affordability of PrEP-
based HIV preventions, focussing on studies published in the past year. In particular, we aim to 
determine the settings and populations in which PrEP is likely to be cost-effective and affordable. 
 
A number of literature reviews on the cost-effectiveness of PrEP have been performed: some 
specific to the US (22) and some more general (23). A previous literature review of cost-effectiveness 
studies in the US (all in MSM), concluded that there was substantial variation in the cost per QALY 
gained. The wide variation reflects the variation in the effectiveness assumed as well as the different 
type of models used, statics rather than dynamic. Gomez et al. (23) systematically reviewed the 
literature on cost-effectiveness of PrEP. The populations modelled were heterosexual couples, men 
who have sex with men (MSM) and people who inject drugs in generalised and concentrated 
epidemics from Southern Africa, Ukraine, USA, and Peru. They pointed out that offering PrEP to key 
populations appeared to be the most cost-effective strategy and that PrEP had the potential to be a 
cost-effective component of HIV prevention. The factors found to be most influential were costs, 
epidemic context, coverage of the prevention programme, the degree to which PrEP is targeted at 
population with high HIV incidence and adherence (affecting effectiveness).  We now focus on the 
most recent studies to add to this literature. 
 
Recent studies: search criteria and summary modelling considerations 
In order to identify the most recent studies of interest the following terms (“cost” AND (“tenofovir” 
OR “pre-exposure prophylaxis” OR “chemoprophylaxis” OR “PrEP”) AND “HIV”) were used to search 
all databases in the Web of Science, starting from 1st July 2014. Eighty-three abstracts were 
retrieved and seven were identified as eligible as they contained either an evaluation of the  cost-
effectiveness of PrEP or an estimation of the cost of delivering PrEP (See Table 2).  
 In terms of the type of mathematical model used in these seven studies, one used a static decision 
model(24), three a dynamic deterministic compartmental model(25-27), one a dynamic stochastic 
microsimulation model(28), while two did not use mathematical models, either because they simply 
used the number needed to treat to estimate the average cost of the PrEP interventions to prevent 
one infection(29) or estimated the resources required to deliver PrEP and did not evaluate the  cost-
effectiveness of introducing it(30). The difference between static and dynamic models is that static 
models, typically used in health economics, do not take into account the fact that HIV is an infectious 
diseases and therefore that by  preventing directly one infection, more (secondary) infections are 
likely to be averted(31).  
 
Recent studies: Model comparisons and main epidemiological assumptions 
Summary details of the studies are provided in Table 2.  Of the seven studies we identified, three 
were among MSM(24, 25, 29), three in heterosexual sero-different couples(26-28) and one in the 
general population attending primary health care clinics(30). Those conducted among MSM were all 
North American - from the US in general(24), Los Angeles(25) and Canada(29).  The studies that 
focussed on sero-different couples were conducted from an African perspective - South Africa(28), 
Nigeria(26) and Uganda(27) and finally there was one based on attendees at primary health care 
clinics in South Africa(30).  We will focus here primarily on the five published cost-effectiveness 
studies (not the abstract(25)). 
 
All of the cost-effectiveness studies compared the introduction of PrEP to a scenario in which PrEP is 
not introduced (24-26, 28, 29), although some studies also considered the potential expansion of HIV 
testing and/or eligibility criteria for ART initiation (25, 27). A couple of them considered the 
introduction of PrEP in combination either with condom promotion and ART to all those diagnosed 
with HIV(26) or with an increase in ART coverage in couples at high risk(27).  
Only two studies provided the HIV incidence in the comparator scenario in which PrEP was not 
introduced , being 2.7 per 100 person-years(28) and a median of 5 per 100 person-years (26). 
The effectiveness of PrEP against HIV was assumed to be 44% by Chen & Dowdy and Ouellet et al. 
(24, 29), based on the IPrEx study conducted among MSM in several countries including the US (1) 
(92% in an alternative scenario in Chen&Dowdy), 70% (range: 44-90%) by Mitchell et al.(26), 90% by 
Jewell et al.(28) and 92% (range: 77%-98%) by Ying et al.(27), all based on the Partners PrEP study 
(3).  
 
The duration of the PrEP intervention was one year in the studies conducted among MSM in North 
America (24, 29), for a variable length of time, from enrolment to respectively six months and one 
year since ART initiation of the HIV positive partner in sero-different couples in Uganda(27) and 
South Africa(28), while until HIV acquisition or ART initiation of the positive partner for the HIV 
negative partners in the sero-different couples in Nigeria (26).  
 
Only one study considered the potential impact of a decrease in condom use in people receiving 
PrEP(24) and none of them considered other possible negative consequences of PrEP: such as the 
development of resistance or toxicities due to PrEP, however there is no evidence from the RCTs for 
these to be major issues. 
 
Recent studies: Cost-effectiveness parameters 
The cost assumed for one year of PrEP varies substantially across studies, mainly driven by the 
setting. In South Africa and Nigeria this was assumed to be around $250 per year (26, 28), in Uganda 
this was estimated to be respectively $408 and $92 in the study and government settings (27), while 
in North America it was assumed  around $10,000 per year (range $5,000 to $15,000) (including the 
cost of documenting HIV negative status, renal function tests prior to PrEP initiation, quarterly clinic 
visits, HIV testing, bi-annual screening for STI and bi-annual renal function testing) by Chen et al.(24) 
and $11,760 (Canadian $12,000) by Ouellet et al.(29). 
 
Three of the seven studies considered a societal perspective (this means that the cost and benefit 
incurred by the society as a whole are taken into account: direct medical and non-medical costs (e.g. 
patient transportation to attend the clinic), indirect costs (e.g. time lost from work) and intangible 
costs (e.g. pain and suffering))(24, 25, 29), one study took a health care system perspective(28), two 
the provider perspective(26, 27). The studies conducted among MSM in North America considered a 
lifetime horizon(24, 29), while the studies among sero-different couples in Nigeria and South Africa 
used a time horizon of 20 years(26, 28) and the one in Uganda 10 years (27).  All the  cost-
effectiveness studies discounted the costs and effects using an annual discount rate of 3% per 
year(24, 27-29), with the exception of Mitchell et al. (26) that used an annual discount rate of 10% 
per year, due to the high predilection for present in Nigeria. 
All  cost-effectiveness studies used as measure of health benefit used either the DALYs averted (26-
28) or the QALYs gained(24, 29) and some in addition considered infections averted(26, 27). The 
disability weights for HIV positive people used were taken either from a meta-analysis (32) 
conducted few year ago (24, 29), or from the Global Burden of Disease study performed in 2004(33) 
or in 2010(26, 27, 34).  
Finally, regarding the cost-effectiveness threshold used, only the studies set in Africa (26, 27) 
reported this explicitly. They used a  cost-effectiveness threshold of three times gross domestic 
product (GDP) per capita to be cost-effective and one time GDP per capita to be considered very 
cost-effective(35), as was used in previous WHO material, which is considered unlikely for low and 
middle income countries, given in the UK it has been estimated to be around 0.4 of the GDP per 
capita(36). 
 
Cost-effectiveness of Pre-Exposure Prophylaxis in MSM in North America 
Chen & Dowdy(24) estimated the introduction of PrEP for one year (44% efficacious) among HIV 
negative MSM living in the US will cost $160,000/QALY gained over a lifetime horizon (95% 
uncertainty range: cost saving to $740,000) in the base case. However they considered alternative 
scenarios which made PrEP cost-saving (when an HIV prevalence of 0.35 and high adherence to PrEP 
-  such that the PrEP efficacy was 92% - were assumed) and on the other hand scenarios which 
increased the ICER up as far as $840/QALY gained (in the case of 100% condom use). 
 
Most recently, Ouellet et al.(29) evaluated the cost-effectiveness of one year of ‘on demand’ PrEP 
(as used in the Ipergay trial(2)), among non-injection drug-using MSM in Canada. They used the 
number –needed-to-treat;  51.78, estimated from the iPrEx trial), to calculate the total number of 
non-injection drug-using MSM needed to be on PrEP to prevent one HIV infection and estimated the 
lifetime cost of living with HIV, assuming infections occur at age 30, with a life-expectancy of 35.2 
years. They found that at 0% and 3% discount rates the PrEP intervention was cost-saving, while 
when using a 5% discount rate the ICER varied from Canadian $47,338/QALY gained, in the most 
expensive scenario (1 Canadian $ = 0.98 US$), to Canadian $60,223 in the least expensive case. 
 
The three studies(24, 25, 29) present significant differences in the base case ICER: from cost-
saving(29) to $160,000/QALY gained(24). However, given Chen & Dowdy used a static model, which 
does not take into account secondary infections averted, we would expect this study to obtain less 
favourable ICERs. In addition, even this study found PrEP to be a cost-saving option in situations 
characterized by high adherence (corresponding to a PrEP efficacy of 92%) and being used in a high 
HIV prevalence population (0.35). Importantly, studies recently published on the cost-effectiveness 
of PreP in high income countries have started taking a societal perspective, allowing them to take 
into account the cost incurred by the entire society and therefore some of the advantages of 
keeping people free from HIV.  Unfortunately, none of these studies conducted a budget impact 
analysis necessary to determine its affordability. 
 Cost-effectiveness of Pre-Exposure Prophylaxis among sero-different couples in Africa 
Before this last year, only one study had evaluated the cost-effectiveness of PrEP among sero-
different couples (37). They had found that PrEP could be highly cost-effective in this population 
group and even cost-saving. They estimated that if the annual cost of PrEP is less than 40% the 
annual cost of ART and if PrEP is more than 70% effective then offering PrEP to the HIV-negative 
partner could be at least as cost-effective as initiating ART earlier in the positive one.   
Recently, three studies evaluated the cost-effectiveness of PrEP among sero-different couples in 
Africa (26-28). 
Jewell et al.(28) envisaged an intervention where PrEP (90% efficacious against HIV) would be used 
by the HIV uninfected partner of sero-different couples living in South Africa before the HIV positive 
partner initiates ART and for one year thereafter. They found that this intervention with (33% 
efficacy against HSV-2) or without protection against HSV-2, would be cost-effective , with ICERs 
(over 20 year time horizon) of respectively $9,757 and $10,383/DALY averted (South Africa GDP in 
2012 $7,314). In the sensitivity analyses they found that if all couples were sero-different not only 
for HIV but for HSV-2 as well, the ICER could be further reduced to $1,445/DALY averted. 
Mitchell et al. (26) compared the cost-effectiveness of condom 
promotion, treatment as prevention, PrEP and their combination 
against a baseline scenario characterized by eligibility criteria for 
ART initiation of CD4≤350 cells/mm3 for sero-different couples in 
Nigeria. They found that the most cost-effective strategy was 
condom promotion with an ICER of $1206/DALY averted, followed 
by condom promotion in combination with treatment as 
prevention (ICER: $1,607/DALY averted), followed by the addition 
of PrEP  (ICER: $7870/DALY averted). The order of incrementally 
cost-effective interventions remained the same when varying the 
discount rate (range: 3%-15%), initial PrEP coverage (range: 40-
80%) or initial condom promotion coverage (range: 40-80%). 
However, with a discount rate of 3% (more commonly used, rather 
than 10%) and with lower initial condom promotion coverage the 
ICERs are reduced. When considering a time-frame of 10 years 
(rather than 20), the most cost-effective intervention became Tasp, 
followed by condom promotion +TasP, while when considering a 
lifetime frame the ICERs are improved. This is due to the fact that 
TasP will have a more immediate effect in averting DALYs by 
improving survival in people at low CD4, while the introduction of 
PrEP has an effect on DALYs later in time, by averting HIV 
infections.Ying et al. (27) estimated the cost-effectiveness of a short-term use of PrEP in HIV 
negative partners of high-risk sero-different couples in Uganda. The PrEP intervention is similar to 
the one described by Jewell et al.(28), but until six rather than twelve months after the HIV positive 
partner’s ART initiation and in combination with an increase in ART coverage (assumed currently 
40% in Uganda) among the HIV positive partners of high-risk sero-different couples. They reported 
that this intervention would be very cost-effective in terms of HIV infections averted, but not cost-
effective in terms of cost per DALY averted ($5,334/DALY). They found that clinical capacity played 
an important role with ICER varying from $4,648/DALY averted with high clinical capacity (1500 
couples annually) to $18,151/DALY averted with low clinical capacity (200 couples annually). When 
varying other relevant assumptions (ART cost at $100/person-year, rather than $269/person-year, 
discount rate of 0%, rather than 3% and drop-out from ART and PrEP programme of 10%, rather 
than 3%) the PrEP intervention remains cost-effective for averting DALYs but not very cost-effective, 
while it remains the most cost-effective strategy for averting HIV infections across all ranges of 
assumptions.   
 
These three studies considered a relatively similar PrEP intervention in sero-different couples, all 
using dynamic models and with a relatively short time frame, either ten or twenty years. The cost-
effectiveness of the PrEP intervention alone, assessed by Mitchell et al. and Jewell et al., varied from 
being dominated (meaning that the intervention costs more and is no more effective than the 
comparator) in Nigeria to a cost of around $10,000/DALY averted in South Africa, where it is cost-
effective. When considering the combination of the PrEP intervention with condom promotion and 
TasP in Nigeria, the addition of PrEP was cost-effective, only after condom promotion and condom 
promotion in combination with Tasp at an ICER of $7,870/DALY averted, while in Uganda a 
programme of PrEP and ART in high risk couples cost $5,334/DALY averted, which means PrEP is 
unlikely to be cost effective in these circumstances.  The ICER threshold for an intervention to be 
considered cost effective is the subject of much debate, and the often used threshold of one or 
three time the per capita GDP is widely considered to be too high (38).     
 
The difficulty in comparing these estimates comes from the fact the possible scenarios included 
differs and so do the countries where these studies are set. In particular there are substantial 
differences in terms of HIV incidence assumed in these couples (2.7 per 100 person-years in the 
study set in South Africa(28) to 5 per 100 person-years in the study set in Nigeria(26)), ART eligibility 
and coverage in the reference scenario (CD4<350 cells/mm3 in the studies set in South Africa and 
Nigeria, with assumed ART coverage of 100% in Nigeria and of CD4<500 cells/mm3 with 40% ART 
coverage in the study in Uganda) and the cost-effectiveness threshold, which is based on the GDP 
per capita ($11,440 for South Africa, $2,742 for Nigeria, $1,681 for Uganda).When considering the 
parameters varied in sensitivity analyses in these three studies, they do not overlap. The parameters 
that were significantly affecting the results are the proportion of couples sero-different for both HIV 
and HSV-2 in Jewell et al.(28), the discount rate and the time frame in Mitchell et al. (26) and the 
clinical capacity in Ying et al.(27). 
 
Recent studies: Costing of delivering Pre-Exposure Prophylaxis 
Only two studies presented a costing for delivery of a PrEP programme. Homan et al. estimated the 
additional cost of using a quality improvement approach to integrate the offer of TDF gel (topical 
PrEP) in primary healthcare clinic and strengthen family planning services in KwaZulu-Natal (South 
Africa)(30). They estimated the resources necessary to introduce the quality improvement approach 
are minimal ($18,660) compared to the cost for gel delivery ($89,500). While Ying et al. conducted a 
micro-costing study within a PrEP implementation project and estimated the cost in the research 
setting and in government setting to be respectively $408 and $92 per couple per year. 
 
Conclusions 
 There has been a move for studies of cost-effectiveness of PrEP to focus on populations at high risk 
of contracting HIV.  All the studies published in the last year all focused on some of the key 
populations: MSM in high income countries and sero-different couples in African countries.  In 
addition, those among sero-different couples envisaged a short-term PrEP intervention but in a 
period of time in which the HIV negative person is considered at high risk of contracting HIV. Clearly 
offering PrEP to subgroups of the population and for periods of time where the person is at 
particularly high risk helps to improve the cost-effectiveness of PrEP. However, identification and 
successful targeting of these subgroups at higher risk of contracting HIV is not always 
straightforward.    
In addition, some studies (23) concluded that the maximum benefit from PrEP introduction could be 
realised if introduced in combination with HIV prevention programmes. 
 Compared to the previous  cost-effectiveness studies of PrEP reviewed, some of the recent studies 
developed further investigation of the role of other prevention interventions (such as expansion of 
HIV testing and ART) in combination or as alternatives to PrEP, some(26) found that PrEP would not 
be the most cost-effective, but all found it to be cost-effective as an addition (when considering a 
time frame of 20 years).  Unfortunately, most studies do not report the HIV incidence which is clearly 
a key parameter in determining the cost-effectiveness of PrEP introduction (with PrEP more likely to 
be cost effective if incidence is high) and that could help explain the difference in results.   The 
appropriate cost- effectiveness threshold to be using in a given setting remains a key issue that is not 
fully resolved.   
 
The other crucial element to determine the cost-effectiveness of any intervention is clearly its cost 
and the cost of its delivery. Ongoing implementation projects are paramount to inform countries on 
how to deliver PrEP (who, where, how), how much it will cost and what level of capacity is necessary 
to make it cost-effective.  Most of the studies presented cost-effectiveness analyses, but not budget 
impact analyses, with the exception of Ying et al. which estimated, by conducting a micro costing 
study, the expenditure within a PrEP implementation project and extrapolated the cost if the 
programme was to be run by the government. Budget impact analyses are extremely important for 
health providers when  deciding  whether to introduce PrEP and are increasingly requested by 
reimbursement authorities (39).  The cost-effectiveness of an intervention does not in itself imply 
affordability. This means that even if an intervention is found cost-effective and if the country 
typically uses this criterion to decide on how to distribute the resources on health, this does not 
mean it will make the policy decision to pay to introduce them.   The use of Sofosbuvir for treatment 
of hepatitis C is an example of this in the UK (40)).  
 
 
Key points: 
 Based on studies in the past year, among MSM in North America the estimated cost-
effectiveness of PrEP ranges from cost-saving to $160,000/QALY gained reflecting 
differences in efficacy (86% vs 44%) and type of model used.   
 Among heterosexual sero-different couples the introduction of PrEP is cost-effective 
in South Africa when considering a relatively short term used (until one year after 
the HIV positive partner has initiated ART ), but not in Uganda, unless we consider 
the cost per infection averted. In Nigeria, the introduction of PrEP was not found to 
be cost-effective on its own, but was in combination with condom promotion and 
offer of ART at diagnosis, after these have been implemented. 
 To help decisions of public funding of PrEP, given the current economic situation, 
efforts should be made to evaluate not only the cost-effectiveness but also the 
budget impact of PrEP. 
 All recent  cost-effectiveness studies published as manuscripts find circumstances 
(e.g. higher prevalence, as a proxy of HIV incidence, short term use during a period 
of high risk, higher adherence and therefore effectiveness, in combination with ART 
at diagnosis and condom promotion, or with high clinical capacity) in which PrEP, in 
principle, could be cost-effective, if not cost-saving.  
 It is now time to consider in more detail the PrEP implementation factors, including 
the uptake, the actual way of identifying subgroups of the population at high risk of 
contracting HIV,  the length of the PrEP intervention, related to the actual risk, and 
clearly the actual cost of delivering PrEP. 
 
Tables 
 
Table 1. Guidelines and Position statements on Pre-Exposure Prophylaxis Use and how they addressed issues of costs, cost-effectiveness, and 
affordability 
Year Setting Body Title Issues of costs, cost-effectiveness and affordability Citation 
Jan 
2011 
US CDC Interim Guidance: Pre-exposure Prophylaxis for the 
Prevention of HIV Infection in Men Who Have Sex with 
Men 
Not mentioned. In the Editorial note it is highlighted the 
importance of ensuring “patients understand the financial 
implications of starting PrEP”. 
(41) 
Jan 
2012 
UK BHIVA/ 
BASHH 
The British HIV Association/British Association for Sexual 
Health and HIV Position Statement on pre-exposure 
prophylaxis in the UK 
Cost is mentioned as a concern if PrEP had to be widespread used 
in the UK. In addition, they stated that “It is imperative to gather 
evidence for the value of PrEP in the UK”.  
(42) 
Jun 
2012 
South 
Africa 
Southern 
African 
Clinicians 
Society 
Southern African guidelines for the safe use of pre-
exposure prophylaxis in men who have sex with men 
who are at risk for HIV infection 
Not mentioned. (43) 
Jul 
2012 
World-
wide 
WHO Guidance on Pre-Exposure oral Prophylaxis (PrEP) for 
serodiscordant couples, men and transgender women 
who have sex with men at high risk of HIV: 
Recommendations for use in the context of 
demonstration projects 
The authors highlighted that despite resource costs being 
collected during the trials, there is poor understanding of their 
applicability outside this context. They reviewed the cost-
effectiveness studies published at the time and recommended 
PrEP, taking into account the estimated potential cost-
effectiveness of PrEP. 
Out of pocket costs are mentioned one of the factors influencing 
PrEP acceptability. 
They underlined the need for demonstration projects and 
specified that countries will need to evaluate the best allocation of 
their available resources for HIV prevention, taking in account of 
the potential role of PrEP. 
(44) 
Aug 
2012 
US CDC Interim Guidance for Clinicians Considering the Use of 
Pre-exposure Prophylaxis for the Prevention of HIV 
Infection in Heterosexually Active Adults 
Not mentioned. (45) 
May 
2014 
US US Public 
Health 
Service 
Pre-Exposure Prophylaxis for the prevention of HIV 
infection in the United States - 2014 A clinical practice 
guidelines 
Low out-of-pocket costs are mentioned as one of the most 
important factor for being adherent to medications by chronic 
diseases patients. 
(46) 
Jul 
2014 
World-
wide 
WHO Consolidated guidelines on HIV prevention, diagnosis, 
treatment and care for key populations 
Costs and financial implications have been taken into account 
when establishing the strength of the recommendations, included 
in this guidelines. Regarding PrEP, they concluded that there was 
variability regarding its cost-effectiveness, highly dependent on 
the drug price.  
(47) 
Apr 
2015 
Europe ECDC Evidence suggests that the use of pre-exposure 
prophylaxis (PrEP) for men who have sex with men 
(MSM) is an effective HIV prevention tool for Europe. 
Not mentioned (48) 
BHIVA: British Association for Sexual Health and HIV; CDC: Centers for Disease Control and Prevention; ECDC: European Centre for Disease Control and Prevention ; UK: United Kingdom; US: 
United States; WHO: World Health Organization; 
  
Table 2. Recent studies of the cost–effectiveness of Pre-Exposure HIV Prophylaxis^ 
 
 Chen et al.(24) Drabo et al.(25) Ouellet et al.(29)  Jewell et al.(28) Mitchell et al.(26) Ying et al. (27) 
Type of 
publication 
Peer-reviewed paper Conference abstract Peer-reviewed paper Peer-reviewed paper Peer-reviewed paper Peer-reviewed paper 
Setting and 
population 
MSM in the US MSM in LA County 
(US) 
Non-injection drug-
using MSM in Canada 
Heterosexual sero-
different couples in 
KwaZulu-Natal (South 
Africa) 
Heterosexual sero-
different couples in 
Nigeria 
High risk* 
heterosexual sero-
different couples in 
Uganda (the Partner 
Demonstration 
Project) 
Model type Static decision Dynamic 
deterministic 
compartmental 
No mathematical 
model used. NNT 
used to estimate the 
ICER 
Dynamic stochastic 
microsimulation  
Dynamic 
deterministic 
compartmental  
Dynamic 
deterministic 
compartmental 
Duration and type 
of PrEP 
intervention 
1 year of daily PrEP NA 1 year of on demand 
PrEP 
Daily PrEP used by 
the HIV uninfected 
partner before the 
HIV positive partner 
initiates ART and for 
one year thereafter 
PrEP used by 60% of 
HIV uninfected 
partners, until the 
first event among: 
ART initiation of the 
HIV positive partner, 
HIV acquisition or 
death. 
PrEP used by 80% of 
HIV uninfected 
partners before the 
HIV positive partner 
initiates ART and for 
6 months thereafter 
(6% drop out rate) 
and ART in 40% of 
those with CD4≤500 
cells/mm3, but 80% 
of all HIV positive 
partners in high-risk 
sero-discordant 
couples. 
Comparator 
scenario 
No PrEP (ART 
initiation NA; 36% of 
HIV positive partners 
on ART) 
No PrEP (ART 
initiation at CD4≤500 
cells/mm3) 
No PrEP No PrEP (ART 
initiation at CD4≤350 
cells/mm3) 
No PrEP (ART 
initiation at CD4≤350 
cells/mm3) 
No PrEP (ART in 60% 
of those with 
CD4≤200 cells/mm3, 
in 50% of those with 
CD4 200-350 
cells/mm3 and 10% of 
those with CD4 350-
500 cells/mm3; 
overall 40%) 
HIV incidence or 
prevalence 
0.53% baseline risk of 
HIV acquisition per 
sex act (0.19 HIV 
prevalence) 
NA NA HIV incidence of 2.7 
per 100 person-years 
HIV incidence 
between 2 and 9 per 
100 person-years 
(median 5 per 100 
person-year) 
NA 
PrEP effectiveness 44% based on IPrEx 
study (92% in 
alternative) 
NA 44% based on IPrEx 
study 
90% based on 
Partners PrEP study 
70% (44%-90%) 
based on Partners 
PrEP study 
92% (77%-98%) 
based on Partners 
PrEP study 
Cost of PrEP (US 
$) 
$10,000 (range: 
$5,000 - $15,000) per 
year 
NA $11,760 (Canadian 
$12,000) per year 
$250 per year $118 (range: $82.6-
$153.4) for PrEP 
initiation, $233 
(range: $163.1-
$302.9) per year. 
$408 in the study 
setting, $92 in the 
government setting. 
Perspective of the 
analysis 
Societal Societal Societal Health care Provider Provider 
Time horizon  Lifetime NA Lifetime 20 years 20 years 10 years 
Annual discount 
rate 
3% NA 0%, 3% and 5% 3% 10% (3% and 15% in 
sensitivity analyses) 
3% (0% and 10% in 
sensitivity analyses) 
Outcome 
measure 
ICER (Cost per QALY 
gained) 
ICER (Cost per QALY 
gained) 
ICER (Cost per QALY 
gained) 
ICER (Cost per DALY 
averted) 
ICER (Cost per DALY 
averted and per 
infection averted) 
ICER (Cost per DALY 
averted and per 
infection averted)  
Source for 
disability 
weights/utilities 
Meta-analysis (32); 
Global Burden 
Disease Study 2004 
(33) 
NA Meta-analysis (32) Global Burden of 
Disease study 2010 
(34) and the Iran 
Burden of Disease 
and Injury Study, 
2003 (49) 
 Global Burden of 
Disease study 2010 
(34) 
Global Burden of 
Disease study 2010 
(34) 
CE threshold NA NA NA Cost-effective if ICER 
<3 times South Africa 
GDP per capita 
Cost-effective if ICER 
<3 times Nigeria GDP 
per capita ($8,226) 
per DALY averted; 
highly cost-effective 
if ICER <1 time 
Nigeria GDP ($2,742).           
Cost-effective if ICER 
<3 times 2012 
Uganda GDP per 
capita ($5,043). Very 
cost-effective if ICER 
<1 time 2012 Uganda 
GDP per capita 
($1,681). 
ICER of PrEP 
intervention in 
the base care (US 
$ if not specified) 
$160,000/QALY 
gained (95% UR: cost 
saving -$740,000); 
$26,000/QALY 
gained; 
At 0% and 3% 
discount rate: cost-
saving; 
At 5% discount rate: 
range from 
$46,000/QALY gained 
in the most expensive 
scenario $59,000 in 
the least expensive. 
$9,757/DALY averted, 
assuming 33% 
efficacy of PrEP 
against HSV-2 and 
$10,383/DALY 
averted, assuming no 
efficacy against HSV-
2. 
Condom promotion 
was the most cost-
effective strategy 
($1206/DALY 
averted)-effective is 
condom promotion in 
combination with 
ART at diagnosis 
($1,607/DALY 
averted) and only at 
this point the 
addition of PrEP 
would be cost-
effective 
($7,870/DALY 
averted). 
A programme of PrEP 
and ART: $1,340 per 
infection averted and 
$5,334 per DALY 
averted; 
A programme of ART 
alone (in 90% of 
those with CD4≤500 
cells/mm3): $1,452 
per infection averted 
and 1,075 per DALY 
averted. 
 
ICER (expressed in 
US $) in 
sensitivity 
analyses 
Higher level of HIV 
prevalence and high 
adherence to PrEP: 
cost-saving; 
100% condom use: 
$840/QALY gained; 
NA Range presented in 
the base case. 
If all couples sero-
different for HIV both 
HIV and HSV-2: 
$1,445/DALY averted 
 
With 15% discount 
rates cost-
effectiveness is 
reduced. With 3% 
discount rate the 
order of cost-
effectiveness among 
interventions is the 
Clinical capacity: high 
(1500 couples 
annually) ICER of 
$4,648/DALY averted; 
low (200 couples): 
$18,151/DALY 
averted. 
With ART cost at 
$100/person-year, 
same but the ICERs 
are lower. 
With a time-frame of 
10 (rather than 20) 
years, TasP is the 
most cost-effective 
intervention, 
followed by condom 
promotion +TasP. 
The initial PrEP 
coverage (40 and 
80% rather than 60%) 
had a small impact on 
DALYs averted, 
although had an 
impact on total costs. 
Lower initial condom 
promotion coverage 
(40 or 60% rather 
than 80%) reduced to 
some extent both 
costs and DALYs 
averted, and cost per 
DALY, but the order 
remained the same. 
0% annual 
discounting, 10% 
drop-out from ART 
and PrEP programme 
is cost-effective for 
averted DALY but not 
very cost-effective. 
PrEP remains the 
most cost-effective 
strategy for averting 
HIV infections across 
all ranges of 
assumptions. 
Costs are in US dollars if indicated as $.  
ART: antiretroviral therapy; CE: cost-effectiveness; DALY: disability-adjusted life-year; ICER: incremental cost-effectiveness ratio; LA: Los Angeles; MSM: men having sex with men; NA: not 
available; NNT: number needed to treat; PrEP: Pre-Exposure Prophylaxis; QALY: quality-adjusted life-year; STI: sexually transmitted infections; UR: uncertainty range; US: United States;^The 
costing study by Homan et al. is not included in this table, as it did not evaluate the PrEP cost-effectiveness. 
*defined as couples where the HIV negative partner is aged <25 years and belongs to the top 15th percentile in the number of casual sex partners;
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